ReviewBioconjugate chemistry2018
Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.
Review in Bioconjugate chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Antibiotic Alternatives and Next-Generation Therapeutics forAntibiotics (Basel, Switzerland) · 2025Review
- Bacterial exotoxins in medicine: potential value and perspectives.International journal of medical sciences · 2025Review
- Unveiling the promise: Exosomes as game-changers in anti-infective therapy.Exploration (Beijing, China) · 2024Review
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Cell Membrane-Coated Nanoparticles for Dental, Oral, and Craniofacial Diseases.Research (Washington, D.C.) · 2024Review
- Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective.Drug delivery · 2023Review
- Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines.Toxins · 2023Review
- Biomimetic semiconducting polymer dots for highly specific NIR-II fluorescence imaging of glioma.Materials today. Bio · 2022Article
- Biomimetic Neutrophil Nanotoxoids Elicit Potent Immunity againstNano letters · 2022Article
- Subunit vaccines forFrontiers in immunology · 2022Review
- Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities.Vaccines · 2021Review
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Recent progress in targeted delivery vectors based on biomimetic nanoparticles.Signal transduction and targeted therapy · 2021Review
- Bacteria-Inspired Nanomedicine.ACS applied bio materials · 2021Review
- Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response.Biomicrofluidics · 2021Review
- Nanotechnology for virus treatment.Nano today · 2021Review
- CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells.Theranostics · 2021Article
- Polymeric nanoparticle vaccines to combat emerging and pandemic threats.Biomaterials · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As nanoparticles exhibit unique properties attractive for vaccine development, they have been progressively implemented as antigen delivery platforms and immune potentiators. Recently, cell membrane-coated nanoparticles have provided a novel approach for intercepting and neutralizing bacterial toxins by leveraging their natural affinity to cellular membranes. Such toxin-nanoparticle assemblies, termed nanotoxoids, allow rapid loading of different types of toxins and have been investigated for their ability to effectively confer protection against bacterial infection. This topical review will cover the current progress in antibacterial vaccine nanoformulations and highlight the nanotoxoid platform as a novel class of nanoparticulate vaccine. We aim to provide insights into the potential of nanotoxoids as a platform that is facile to implement and can be broadly applied to help address the rising threat of super pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.